In congenital myopathies (including related RYR1) a possible pharmacological treatment can include three main objectives: the direct modification of the altered function of the protein; better interactions between thin and thick filaments (for example, in some nemaline myopathies); and therapies aimed at nonspecifically ameliorating the downstream effects of the specific gene mutation [59]. This evidence concerns the gene RYR1 and congenital myopathy.